Business
ARIUS to present update on antibody development targeting cancer antigens at European and U.S. conferences
ARIUS to present update on antibody development targeting cancer antigens at European and U.S. conferences.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Dec. 5 /CNW/ - ARIUS Research Inc. (\"ARIUS\" or the \"Company\")\n(TSX: ARI) announced today that it will present an update on its use of\ntherapeutic antibodies to discover and target cancer antigens at The European\nAntibody Congress 2006 to be held December 4-6, 2006 in Lyon France.\n\n\nHelen Findlay, Vice President of ARIUS will present a case study on\n'Drugs versus Targets, an Alternative Discovery Strategy'.\n\n\n\"ARIUS' FunctionFIRST Platform expands on the value of drug discovery by\ndelivering not only drug candidates but novel targets, epitopes and signaling\npathways. Ultimately though our goal is to treat patients but the drugs need\nto be developed first,\" said Ms. Findlay.\n\n\nIn addition, Dr. Daniel Pereira, Vice President Research at ARIUS, will\nbe presenting on 'The Identification and Development of Therapeutic Antibodies\nTargeting a Variety of Novel Cancer Anitgens' at the IBC Lifesciences,\n4th Annual Antibody Therapeutics Conference, December 12-14, 2006 in\nSan Diego, California.\n\n\n\"ARIUS is pleased to have the opportunity to update the IBC delegates on\nits lead CD44, CD59 and TROP-2 antibody candidates selected for clinical\ndevelopment and its growing pipeline of anti-cancer antibodies discovered\nusing the proprietary FunctionFIRST(TM), platform,\" said Dr. Pereira.\n\n\nAbout ARIUS\n\n\nARIUS Research Inc. is a biotechnology company dedicated to personalizing\ncancer therapy through the discovery and development of novel anticancer\nmonoclonal antibodies (MAbs). Established in 1999, ARIUS has built a\nproprietary technology platform, FunctionFIRST(TM), that rapidly identifies\npowerful MAbs targeting a variety of cancer indications. This antibody\ngeneration engine has enabled ARIUS to assemble a growing pipeline, which is\nused for commercial collaborations and in-house development. ARIUS has ongoing\npartnerships with key biotechnology and drug development companies. The\nCompany is listed on the TSX under the symbol \"ARI\".\n\n\nForward-Looking Statement\n\n\nCertain statements in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown risks, uncertainties and other\nfactors that may cause our actual results to be materially different from any\nfuture results...